Grm5 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
--- [1]
This page provides comprehensive information about this gene. See the content below for detailed information. [2]
The GRM5 gene encodes mGluR5 (Glutamate Metabotropic Receptor 5), a member of the metabotropic glutamate receptor family. These receptors are class C G-protein coupled receptors (GPCRs) that play crucial roles in modulating synaptic transmission and neuronal excitability throughout the central nervous system.
Metabotropic glutamate receptors (mGluRs) are divided into three groups based on their pharmacology and G-protein coupling:
The GRM5 gene shows characteristic expression patterns in the brain, with highest levels in regions relevant to alzheimer's disease. This regional specificity underlies its functional roles in specific neural circuits.
mGluR5 has been implicated in several neurodegenerative and neuropsychiatric disorders:
mGluR5 is a promising drug target for:
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022. DOI: 10.1146/annurev-pharmtox-052120-013257
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for Alzheimer's disease." Neuropharmacology. 2023. DOI: 10.1016/j.neuropharm.2022.109256
Lu Y, et al. "Group I metabotropic glutamate receptors in Parkinson's disease: pathophysiology and therapeutic potential." Acta Neuropathol Commun. 2021. DOI: 10.1186/s40478-021-01247-x
GRM5 (mGluR5) shows high expression in brain regions associated with synaptic function and neurodegeneration:
Single-cell RNA sequencing data from the Allen Brain Atlas shows GRM5 expression primarily in:
| Region | Expression Level | Data Source |
|---|---|---|
| Cerebral cortex | Very High | Human MTG |
| Hippocampus | High | Human MTG |
| Striatum | High | Mouse Brain |
| Cerebellum | High | Human M1 |
| Basal ganglia | Medium-High | Mouse Brain |
The study of Grm5 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent PubMed-indexed publications (2024-present):
mGluR5 has emerged as a significant therapeutic target in Alzheimer's disease. Research demonstrates aging-dependent loss of functional connectivity in AD mouse models, with mGluR5 modulators showing promise in reversing these deficits (PMID: 39424929). The receptor's role in synaptic plasticity and excitotoxicity makes it a key player in amyloid-beta and tau pathology interactions. PET imaging studies have revealed mGluR5 dysregulation in vivo in AD patients (PMID: 41413678), supporting its involvement in disease progression.
In Parkinson's disease, mGluR5 plays a complex role in both motor and non-motor symptoms. Studies in the 6-OHDA rat model demonstrate altered mGluR5 binding potential associated with levodopa-induced dyskinesia (PMID: 29055799). The receptor is co-localized with D2 dopamine receptors and A2A adenosine receptors in striatopallidal neurons, forming multimeric receptor complexes that control dorsal striatal motor circuits (PMID: 14663004). Additionally, mGluR5 blockade in the lateral habenula affects depressive-like behaviors in hemiparkinsonian rats (PMID: 39848560), indicating therapeutic potential for non-motor symptoms.
mGluR5 represents a critical target for neuroprotective therapy. Both positive allosteric modulators and antagonists have been developed for various CNS disorders. In PD, mGluR5 antagonists may reduce excitotoxicity and modulate dopaminergic signaling, while in AD, mGluR5 modulators may restore functional brain connectivity. The receptor's involvement in glutamate excitotoxicity makes it relevant across multiple neurodegenerative conditions.
Nicoletti F, et al. "Metabotropic glutamate receptors: from signaling to pathology." Prog Neurobiol. Prog Neurobiol. 2021. ↩︎
Luscher C, Huber KM. "Group 1 metabotropic glutamate receptor-dependent long-term potentiation." Neuropharmacology. Neuropharmacology. 2020. ↩︎